Mark W. Frohlich

Mark Frohlich is the current CEO at Indapta Therapeutics. Mark has over 25 years of experience in the biotechnology industry, specializing in oncology drug development.

Frohlich began their career at Dendreon Corporation in August 2005 as EVP R&D and Chief Medical Officer. Mark then moved to Juno Therapeutics in January 2014, where they served as Executive Vice President of Portfolio Strategy. In October 2017, they became a Consultant for Innovative Drug Development, LLC. Mark has also served on several scientific advisory boards for oncology biotechnology companies.

Frohlich has been with Indapta Therapeutics since its inception and has played a vital role in its success. Under their leadership, the company has developed groundbreaking new therapies for cancer patients. In recognition of their achievements, they were named CEO in February 2022.

Mark W. Frohlich attended Kinnelon High School. Mark then went on to Yale University and graduated with a BS in Economics and Electrical Engineering. After that, they attended the Swiss Federal Institute of Technology where they received a degree in Computer Engineering. Afterwards, they attended Harvard Medical School and received their Doctor of Medicine - MD. Finally, they completed an Internal Medicine Residency Program and Chief Residency at the University of California, San Francisco. Mark is currently completing an Oncology Fellowship Program at the University of California, San Francisco.

Some direct reports include Guy DiPierro - Chief Strategy Officer & Co-Founder, Austin Bigley - VP, Research, and Robert Sikorski - Chief Medical Officer.